肿瘤治疗新技术 医术天地

  • 用微信扫描以下二维码

    更多移动资讯等着你

  • 抗癌故事

肿瘤治疗新技术

首页
/
最新疗法
/
抗癌故事
/
癌症论坛
/
抗癌头条
/
名医博客
/
肿瘤问答
/
医学文献
/
健康大数据
/

Tarceva联合吉西他滨治疗胰腺癌 017

楼主:云底下的星星2017-03-21 05:39 只看楼主

马上注册,结交更多好友,享用更多功能,让你轻松玩转社区。

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
导读:Tarceva联合吉西他滨治疗胰腺癌
         [/td]  
Data from Phase III Study Show Tarceva Plus Gemcitabine Significantly Improves Survival Compared to Gemcitabine Alone in Advanced Pancreatic Cancer Patients
Thursday January 27, 11:05 am ET
Tarceva is the Only Epidermal Growth Factor Receptor (EGFR) Therapy to Show an Improvement in Survival in Pancreatic Cancer
HOLLYWOOD, Fla.--(BUSINE WIRE)--Jan. 27, 2005-- OSI Pharmaceuticals, Inc. , Genentech, Inc. , and Roche (SWX Zurich) aounced today that a randomized Phase III clinical study of Tarceva(TM) (erlotinib) plus gemcitabine chemotherapy in patients with locally advanced or metastatic pancreatic cancer met its primary endpoint by demotrating a statistically significant 23.5 percent improvement in overall survival when compared to patients receiving gemcitabine plus placebo. The data were presented at the Second Aual Gastrointestinal Cancers Symposium in Hollywood, Fla. Tarceva is the first drug shown in a Phase III trial to prolong survival when added to the standard of care (gemcitabine) in the treatment of patients with previously untreated advanced pancreatic cancer.
Results from the Pancreatic Cancer Study
The study data demotrated an improvement in overall survival for patients receiving Tarceva plus gemcitabine compared to patients receiving gemcitabine plus placebo (hazard ratio = 0.81, p-value = 0.025; a hazard ratio of le than one indicates a decreased risk of death and a p-value of le than 0.05 indicates statistical significance). Twenty-four percent of patients receiving Tarceva plus gemcitabine were alive after one year compared to 17 percent of patients receiving gemcitabine plus placebo. Median survival in the Tarceva plus gemcitabine arm was 6.4 months compared to 5.9 months in the gemcitabine plus placebo arm. An exploratory analysis of survival by pre-treatment characteristics also showed that patients with metastatic disease and patients with poor performance status derived a survival benefit. Progreion-free survival in the Tarceva plus gemcitabine arm also was significantly improved (hazard ratio = 0.76, p-value = 0.003), although there was virtually no difference in tumor reoe (9 percent in patients receiving Tarceva plus gemcitabine versus 8 percent in the gemcitabine plus placebo arm).
The international study was a multi-center, randomized, double-blind, placebo-controlled Phase III trial evaluating Tarceva at 100 mg/day or 150 mg/day in patients with locally advanced or metastatic pancreatic cancer. The study randomized patients to receive either gemcitabine plus concurrent Tarceva or gemcitabine plus placebo. Gemcitabine was dosed at 1,000 mg/m2 IV once weekly. A total of 569 patients were randomized in the study, 521 patients were randomized to receive 100 mg/day of Tarceva plus gemcitabine or gemcitabine plus placebo, and 48 patients received 150 mg/day of Tarceva plus gemcitabine or gemcitabine plus placebo. Aroximately 75 percent of the patients in the study had metastatic disease and 25 percent had locally advanced disease. The study had sites in the United States, Asia, Canada, Europe, Australia and South America. The study was conducted by the National Cancer Ititute of Canada Clinical Trials Group based at Queen\'s University, Ontario in collaboration with OSI Pharmaceuticals.
http://www.tumor.cn
A preliminary analysis of the safety data did not reveal any unexpected safety signals beyond that seen in previous studies of Tarceva in both monotherapy and combination settings. As expected, rash and diarrhea were the principal Tarceva related side effects seen in the study. Rash was reported by 72 percent of patients who received Tarceva plus gemcitabine and by 28 percent of patients who received gemcitabine plus placebo. Diarrhea was reported by 51 percent of patients who received Tarceva plus gemcitabine and by 36 percent of patients who received gemcitabine plus placebo.
\"The results of this trial underscore the importance and potential utility of Tarceva in combination with gemcitabine in the treatment of patients with pancreatic cancer,\" stated Malcolm Moore, M.D., Study Chair and Medical Oncologist at Prince Margaret Hoital in Toronto, Canada and Chair of the Gastrointestinal Disease Site, NCIC Clinical Trials Group. \"These Tarceva results represent an important medical advance in the treatment of patients with pancreatic cancer and we hope will open the door to a completely new aroach to treating the disease.\"
\"The positive outcome of this trial is great news for pancreatic patients and their families. OSI is working closely with the FDA to complete a Sulemental New Drug Alication (DA) which we hope to file in the first half of 2005,\" stated Colin Goddard, Ph.D., Chief Executive Officer of OSI Pharmaceuticals. \"Tarceva has now shown a survival benefit in two cancers that are widely recognized among the most difficult to treat, pancreatic cancer and lung cancer.\"



上一篇:乳腺癌致病基因变异可引发胰腺癌
下一篇:胰腺癌流行病学
使用“←” “→”快捷翻页
作者:游客
您需要登录后才可以回帖 登录 | 立即注册

请遵守医术天地社区公约言论规则,不得违反国家法律法规

猜你喜欢

  • 冷冻消融,在肾癌治疗中显优势

  • 万里浪抗癌经验浅谈

  • 香港男女检测需要多少费用 薇信ansen273689

  • 香港测血检测宝宝男女,去香港测血化验宝宝

    友情链接:
    复大官方网站
    -
    亚西亚健康网
    -
    重庆肛肠医院
    -
    名医博客
    -
    抗癌资讯

    sitemap|网站地图|手机版|

    医术天地 (琼B2-20040038-1)

       

    快速回复 返回顶部 返回列表